Adiponectin negatively correlates with alcoholic and non-alcoholic liver dysfunction: Health check-up study of Japanese men

Hepatology Research

Volumn 43, Issue 3, 2013, Pages 238-248

  Hamano, Mina ^a   Kamada, Yoshihiro ^a   Kiso, Shinichi ^a   Furuta, Kunimaro ^a   Kizu, Takashi ^a   Chatani, Norihiro ^a   Egawa, Mayumi ^a   Takemura, Takayo ^a   Ezaki, Hisao ^a   Yoshida, Yuichi ^a   Watabe, Kenji ^a   Hamasaki, Toshimitsu ^a   Umeda, Miyuki ^b   Furubayashi, Aiko ^b   Kinoshita, Kazuo ^b   Kishida, Osamu ^b   Fujimoto, Takashi ^b   Yamada, Akira ^b   Tsukamoto, Yoshifumi ^b   Tsutsui, Shusaku ^a   Takehara, Tetsuo ^a   Hayashi, Norio ^c   Matsuzawa, Yuji ^b   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Alcohol consumption; Central obesity; Fatty liver; Insulin resistance; Liver dysfunction

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; LIVER ENZYME;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FATTY LIVER; HUMAN; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; JAPANESE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84874320840     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01066.x     Document Type: Article

References (54)

1. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
2. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010; 51: 307-28.
3. Hamaguchi M, Kojima T, Takeda N etal. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
4. Lieber CS. Alcohol, liver, and nutrition. J Am Coll Nutr 1991; 10: 602-32.
5. Chitturi S, Farrell G, Hashimoto E etal. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 2007; 22: 778-87.
6. Amarapurkar D, Hashimoto E, Lesmana L etal. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-93.
7. Fan J, Saibara T, Chitturi S etal. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007; 22: 794-800.
8. Lee K, Sung J, Kim J, Park T. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev 2009; 25: 150-5.
9. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12years: analysis of clinical background. J Gastroenterol 2003; 38: 954-61.
10. Speliotes E, Massaro J, Hoffmann U etal. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979-87.
11. Neuschwander-Tetri B. Food energy efficiency, cannabinoids, and a slow death of the weight loss dogma. Hepatology 2007; 46: 12-15.
12. Kamada Y, Nakamura T, Funahashi T etal. Visceral obesity and hypoadiponectinemia are significant determinants of hepatic dysfunction: an epidemiologic study of 3827 Japanese subjects. J Clin Gastroenterol 2009; 43: 995-1000.
13. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
14. Furler S, Gan S, Poynten A, Chisholm D, Campbell L, Kriketos A. Relationship of adiponectin with insulin sensitivity in humans, independent of lipid availability. Obesity (Silver Spring) 2006; 14: 228-34.
15. Hotta K, Funahashi T, Arita Y etal. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
16. Ouchi N, Ohishi M, Kihara S etal. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-4.
17. Hui J, Hodge A, Farrell G, Kench J, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
18. Lemoine M, Ratziu V, Kim M etal. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009; 29: 1431-8.
19. Nazal L, Riquelme A, Solís N etal. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes Surg 2010; 20: 1400-7.
20. Masaki T, Chiba S, Tatsukawa H etal. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-84.
21. Xu A, Wang Y, Keshaw H, Xu L, Lam K, Cooper G. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
22. Kamada Y, Matsumoto H, Tamura S etal. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007; 47: 556-64.
23. Matsumoto H, Tamura S, Kamada Y etal. Adiponectin deficiency exacerbates lipopolysaccharide/d-galactosamine-induced liver injury in mice. World J Gastroenterol 2006; 12: 3352-8.
24. Kamada Y, Tamura S, Kiso S etal. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-807.
25. McFarlane SI, von Gizycki H, Salifu M etal. Alcohol consumption and blood pressure in the adult US population: assessment of gender-related effects. J Hypertens 2007; 25: 965-70.
26. Clerc O, Nanchen D, Cornuz J etal. Alcohol drinking, the metabolic syndrome and diabetes in a population with high mean alcohol consumption. Diabet Med 2010; 27: 1241-9.
27. Bellentani S, Saccoccio G, Costa G etal. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-50.
28. Yamada T, Fukatsu M, Suzuki S, Yoshida T, Tokudome S, Joh T. Alcohol drinking may not be a major risk factor for fatty liver in Japanese undergoing a health checkup. Dig Dis Sci 2010; 55: 176-82.
29. Kawamoto R, Kohara K, Tabara Y etal. Alcohol consumption is associated with decreased insulin resistance independent of body mass index in Japanese community-dwelling men. Tohoku J Exp Med 2009; 218: 331-7.
30. Sierksma A, Patel H, Ouchi N etal. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 2004; 27: 184-9.
31. Costanzo S, Di Castelnuovo A, Donati MB, Iacoviello L, de Gaetano G. Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. J Am Coll Cardiol 2010; 55: 1339-47.
32. Yeomans MR. Alcohol, appetite and energy balance: is alcohol intake a risk factor for obesity? Physiol Behav 2010; 100: 82-9.
33. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
34. Botton J, Heude B, Andre P etal. Relationship between gamma-glutamyltransferase and fat mass in a general population of 8-17years old children. The FLVS II study. Diabetes Metab 2007; 33: 354-9.
35. Stranges S, Dorn J, Muti P etal. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004; 39: 754-63.
36. Fuke Y, Okabe S, Kajiwara N etal. Increase of visceral fat area in Indonesians and Japanese with normal BMI. Diabetes Res Clin Pract 2007; 77 (Suppl 1): S224-7.
37. Utzschneider K, Kahn S. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-61.
38. Ryu M, Kimm H, Jo J, Lee SJ, Jee SH. Association between alcohol intake and abdominal obesity among the korean population. Epidemiol Health 2010; 32: e2010007.
39. Lee MY, Kim MY, Kim SY etal. Association between alcohol intake amount and prevalence of metabolic syndrome in Korean rural male population. Diabetes Res Clin Pract 2010; 88: 196-202.
40. You M, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1-6.
41. Moriya A, Iwasaki Y, Ohguchi S etal. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 378-88.
42. Hiramine Y, Imamura Y, Uto H etal. Alcohol drinking patterns and the risk of fatty liver in Japanese men. J Gastroenterol 2011; 46: 519-28.
43. Wakabayashi I. Cross-sectional relationship between alcohol consumption and prevalence of metabolic syndrome in Japanese men and women. J Atheroscler Thromb 2010; 17: 695-704.
44. Nishise Y, Saito T, Makino N etal. Relationship between alcohol consumption and serum adiponectin levels: the Takahata study - a cross-sectional study of a healthy Japanese population. J Clin Endocrinol Metab 2010; 95: 3828-35.
45. Kawamoto R, Tabara Y, Kohara K etal. Alcohol drinking status is associated with serum high molecular weight adiponectin in community-dwelling Japanese men. J Atheroscler Thromb 2010; 17: 953-62.
46. Stejskal D, Růzicka V, FanfrdLová G, Kolár V, Bartek J. High adiponectin and TNF-alpha levels in moderate drinkers suffering from liver steatosis: comparison with non drinkers suffering from similar hepatopathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149: 93-9.
47. Argentou M, Tiniakos D, Karanikolas M etal. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg 2009; 19: 1313-23.
48. Asano T, Watanabe K, Kubota N etal. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 2009; 24: 1669-76.
49. Yamauchi T, Kamon J, Minokoshi Y etal. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
50. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-26.
51. Marchesini G, Avagnina S, Barantani E etal. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005; 28: 333-9.
52. Oh S, Cho Y, Kang M etal. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006; 55: 1604-9.
53. Kleiner D, Brunt E, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
54. Funahashi T, Matsuzawa Y. Metabolic syndrome: clinical concept and molecular basis. Ann Med 2007; 39: 482-94.